September 24, 2024

Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

On April 29, 2024, tisotumab vedotin-tftv (Tivdak) was granted regular approval for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

The ASCO Post

February 21, 2023

Salpingectomy: Preventing Ovarian Cancer

In this video, gynecologic oncologist, Rebecca Stone discusses the salpingectomy procedure, removal of the fallopian tubes, that is effective at preventing the most common form of ovarian cancer.

Johns Hopkins Medicine

December 06, 2023

'Game-Changer’ Intervention for Ovarian Cancer Prevention

Gynecologic oncologist Rebecca Stone and colleagues at Johns Hopkins are leading the way in salpingectomy — a quick, low-risk surgical intervention that can significantly reduce the risk of ovarian cancer.

Johns Hopkins Medicine

March 28, 2024

Edward Tanner Expands Minimally Invasive Options for Gynecologic Surgery at Sibley

Edward Tanner is director of Johns Hopkins women’s health in the National Capital Region.

Johns Hopkins Medicine

March 29, 2023

Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy

Treatment with the poly (ADP-ribose) polymerase inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse eve...

The ASCO Post

April 25, 2024

Expert Point of View: Gini F. Fleming, MD

Exciting updates from the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer highlight significant improvements in advanced or recurrent endometrial cancer treatment, particularly for patients with specific genetic profiles. Leading expert Dr. Gini F. Fleming shares insights on new approaches and ongoing trials.

The ASCO Post

March 28, 2024

Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

The phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial investigated the efficacy and safety of adding pembrolizumab to chemoradiotherapy in patients with newly diagnosed, high-risk, locally advanced cerv...

The ASCO Post

May 11, 2023

Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma

A new Wee1 kinase inhibitor, adavosertib, showed promising antitumor activity but also raised safety concerns in patients with recurrent or persistent uterine serous carcinoma. The findings were presented by Joyce F. Liu, MD, MPH at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer.

The ASCO Post

May 11, 2023

Expert Point of View: Amanda Nickles Fader, MD

Dr. Amanda Nickles Fader provides insights into GOG 3026, a groundbreaking study offering new hope for low-grade serous ovarian carcinoma with potential implications in treatment paradigms for advanced-stage malignancies.

The ASCO Post